Santelli G, Marfella A, Abate G, Comella P, Nitsch F, Perna M
Tumori. 1986 Apr 30;72(2):139-43. doi: 10.1177/030089168607200204.
We studied urinary excretion levels of neopterin in 30 cancer patients affected by non-Hodgkin's lymphomas, Hodgkin's disease and multiple myeloma compared to 30 healthy subjects. Mean value of neopterin excretion in cancer patients (576.01 +/- 620.37) appeared significantly increased (p less than 0.001) compared to normal controls (134.40 +/- 41.65). A neopterin excretion above the upper normal limit was observed in 23/28 (82%) patients with active disease. A trend to an increased urinary level of neopterin with more advanced stage was observed, namely in patients with bone marrow involvement and constitutional symptoms. We suggest that the evaluation of urinary neopterin levels may be of value in the diagnosis and follow-up of hematologic malignancies.
我们研究了30例患有非霍奇金淋巴瘤、霍奇金病和多发性骨髓瘤的癌症患者的新蝶呤尿排泄水平，并与30名健康受试者进行了比较。癌症患者新蝶呤排泄的平均值（576.01±620.37）与正常对照组（134.40±41.65）相比显著升高（p<0.001）。在23/28（82%）患有活动性疾病的患者中观察到新蝶呤排泄高于正常上限。观察到随着疾病进展新蝶呤尿水平有升高趋势，即在有骨髓受累和全身症状的患者中。我们认为，尿新蝶呤水平的评估可能对血液系统恶性肿瘤的诊断和随访有价值。
